The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLife Science Regulatory News (LABS)

Share Price Information for Life Science (LABS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 39.80
Bid: 39.80
Ask: 40.00
Change: -0.20 (-0.50%)
Spread: 0.20 (0.503%)
Open: 40.10
High: 40.10
Low: 39.80
Prev. Close: 40.00
LABS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sale of Lumen House, Harwell Oxford

1 Dec 2023 07:00

RNS Number : 2798V
Life Science REIT PLC
01 December 2023
 

1 December 2023

LEI: 213800RG7JNX7K8F7525

Life Science REIT plc

("Life Science REIT" or the "Company")

Sale of Lumen House, Harwell Oxford

Life Science REIT (LSE: LABS), the real estate investment trust focused on UK life sciences properties, announces that it has completed the sale of Lumen House for £7.65 million to Harwell Science and Innovation Campus, a joint venture between Brookfield and the UK Atomic Energy Authority together with the Science and Technology Facilities Council. The disposal price represents a 5.6% net initial yield and is 2% ahead of June 2023 book value. 

Lumen House is located on the Harwell Campus in Oxford and with the current occupier soon to vacate the building, presents an attractive development opportunity for the purchaser whilst providing Life Science REIT with additional flexibility to progress more transformational opportunities. These include delivering fully fitted laboratories at Cambourne Park Science and Innovation Campus in Cambridge and progressing the development of Oxford Technology Park. 

Lumen House was acquired in December 2021 for £7.05 million with the disposal achieving a 9% uplift on the acquisition price. 

Simon Farnsworth, Managing Director of Ironstone Asset Management, the Company's Investment Adviser, said: "The economic environment in which Life Science REIT acquired Lumen House is very different to the one we face today and the Company is making capital allocation decisions which reflect that. By realising value from this investment now, we can better focus our efforts and the Company's capital on larger scale opportunities where we are already on site and where we believe that the return profile is more attractive. The fully fitted laboratory initiative at Cambourne Park Science and Technology Campus is a great example of that approach."

END

Enquiries:

Ironstone Asset Management - Investment Adviser

 +44 20 3011 2160

Simon Farnsworth, Managing Director

Simon.farnsworth@ironstoneam.com

Joanna Waddingham, Head of Investor Relations and Corporate Affairs

Joanna.Waddingham@ironstoneam.com

 

 

Link Company Matters Limited - Company Secretary

 

labs_cosec@linkgroup.co.uk

 

 

 

Panmure Gordon (UK) Limited - Joint Corporate Broker

+44 20 7886 2500

Alex Collins / Tom Scrivens

 

 

Jefferies International Limited - Joint Corporate Broker

+44 20 7029 8000

Tom Yeadon / Andrew Morris / Oliver Nott / Harry Randall

 

 

G10 Capital Limited - AIFM

+44 20 7397 5450

Maria Baldwin

 

Buchanan - Financial PR

 

+44 20 7466 5000

Mark Court / Henry Wilson / Verity Parker

LifeSciencereit@buchanan.uk.com

 

Notes to editors

Life Science REIT plc is a specialist property business focused on the UK's growing life science sector. The Company's portfolio of assets is located across the "Golden Triangle" of research and development hubs in Oxford, Cambridge and London's Knowledge Quarter and its strategic vision is to become the property provider of choice for life science companies in the UK.

Life Science REIT is addressing the acute demand-supply imbalance for laboratory space in the "Golden Triangle", which is characterised by low vacancy rates and prime rental increases. The UK life science sector itself is benefiting from a buoyant early stage funding environment, driving demand for laboratory space.

The Company's diverse portfolio of assets ranges from a 20-acre science park currently under development through to fully let buildings, with an important part of the Company's strategy being the conversion of existing properties to laboratory space.

The Company's investment policy is focused on capital growth whilst also providing a growing level of income.

Life Science REIT trades on the Main Market of the London Stock Exchange under the ticker LABS.

Further information is available at https://lifesciencereit.co.uk. To sign up for email alerts, please visit https://lifesciencereit.co.uk/investors/.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DISNKKBNABDDODN
Date   Source Headline
8th May 20245:13 pmRNSHolding(s) in Company
7th May 20247:00 amRNSPurchase of Ordinary Shares by Investment Adviser
1st May 202410:24 amRNSHolding(s) in Company
30th Apr 20241:24 pmRNSHolding(s) in Company
26th Apr 20241:47 pmRNSHolding(s) in Company
25th Apr 20244:23 pmRNSHolding(s) in Company
25th Apr 20244:04 pmRNSNotice of AGM
27th Mar 20247:00 amRNSNew Agreement for Lease at Oxford Technology Park
26th Mar 20247:00 amRNSResults for the year ended 31 December 2023
14th Mar 20241:31 pmRNSHolding(s) in Company
19th Feb 20247:00 amRNSNotice of Full Year Results
13th Feb 202410:12 amRNSHolding(s) in Company
13th Feb 20247:00 amRNSNew Lease at OTP
17th Jan 20249:33 amRNSPurchase of Ordinary Shares by Investment Adviser
9th Jan 20245:29 pmRNSHolding(s) in Company
4th Jan 20247:00 amRNSNew Lease at Oxford Technology Park
14th Dec 20235:20 pmRNSHolding(s) in Company
13th Dec 20234:54 pmRNSHolding(s) in Company
12th Dec 20231:04 pmRNSHolding(s) in Company
4th Dec 20237:00 amRNSNew Lease at Oxford Technology Park
1st Dec 20237:00 amRNSSale of Lumen House, Harwell Oxford
24th Nov 20233:22 pmRNSHolding(s) in Company
23rd Nov 20234:21 pmRNSHolding(s) in Company
13th Nov 20232:21 pmRNSHolding(s) in Company
6th Nov 20235:38 pmRNSHolding(s) in Company
6th Nov 20235:26 pmRNSHolding(s) in Company
19th Oct 202311:20 amRNSHolding(s) in Company
11th Oct 202311:32 amRNSDirector Declaration
2nd Oct 20234:34 pmRNSHolding(s) in Company
25th Sep 202311:52 amRNSHolding(s) in Company
22nd Sep 20235:25 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSHalf Year Results
19th Sep 20231:54 pmRNSHolding(s) in Company
18th Sep 20235:44 pmRNSHolding(s) in Company
4th Sep 202311:29 amRNSHolding(s) in Company
29th Aug 20233:33 pmRNSHolding(s) in Company
2nd Aug 20237:00 amRNSNotice of Half Year Results
21st Jul 20235:53 pmRNSHolding(s) in Company
4th Jul 202312:05 pmRNSHolding(s) in Company
27th Jun 20237:00 amRNSDebt Refinancing
25th May 20234:15 pmRNSResult of AGM
22nd May 20234:44 pmRNSHolding(s) in Company
15th May 20237:00 amRNSNew Lease at Cambourne Business Park
25th Apr 20237:00 amRNSPurchase of Ordinary Shares by Investment Adviser
17th Apr 20237:00 amRNSNotice of Capital Markets Day
4th Apr 202311:39 amRNSPublication of Supplementary Prospectus
27th Mar 20237:00 amRNSResults for the year ended 31 December 2022
23rd Mar 20237:00 amRNSPublication of Cell and Gene Therapy Report
3rd Mar 20237:00 amRNSAttractive Debt Refinancing
1st Mar 20232:34 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.